Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
Abstract Background Interleukin-6 (IL-6) was considered to be with the severity and mortality in COVID-19 patients, which implies a potential therapeutic target for treatment. We aimed to evaluate the safety and initial efficacy of Tocilizumab treatment for COVID-19 patients. Methods In the retrospe...
Main Authors: | Yu Chen, Xijing Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2021-04-01
|
Series: | Intensive Care Research |
Subjects: | |
Online Access: | https://doi.org/10.2991/icres.k.210406.001 |
Similar Items
-
Safety and efficacy of tocilizumab in critically ill patients with COVID-19: an observational study
by: Ghada A. Youssef, et al.
Published: (2023-09-01) -
Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01) -
Efficacy of Tocilizumab in Patients with COVID-19
by: Ahmad Alikhani, et al.
Published: (2022-12-01) -
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01) -
EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)